Cereno Scientific

Historical price data

Cereno Scientific is a clinical-stage biotech focused on developing first-in-class, disease-modifying treatments for rare cardiovascular and pulmonary diseases with high unmet need. The company's strategy leverages orphan drug designations and accelerated pathways to efficiently advance its dual-platform pipeline, led by Phase II candidate CS1 for Pulmonary Arterial Hypertension (PAH). With a Phase II asset, a Phase I candidate, and a preclinical program, Cereno is positioned for value inflection through clinical milestones and potential partnerships.

Dual-platform approach: 1) Epigenetic modulation via HDAC inhibition for disease modification in vascular and fibrotic diseases; 2) Oral, selective prostacyclin (IP) receptor agonism for cardiovascular indications.

Faces competition from both established symptomatic therapies and novel disease-modifying agents in development from large pharma (e.g., Merck's sotatercept in PAH). Differentiation hinges on demonstrating superior disease-modifying efficacy, oral convenience, and favorable safety profiles.